References
- Sharma OP, Defining sarcoidosis. In: Mitchell D, Wells A, Spiro S, Moller D, (eds.) Sarcoidosis. Boca Raton: CRC Press; 2012.
- Thillai M, Wickremasinghe M, Lalvani A, Moller D, Mitchell D. Etiology. In: Mitchell D, Wells A, Spiro S, Moller D. (eds.) Sarcoidosis. Boca Raton: CRC Press; 2012. p.27–40.
- Lyne JC, Savage HO, Oldershaw PJ. The heart. In: Mitchell D, Wells A, Spiro S, Moller D. (eds.) Sarcoidosis. Boca Raton: CRC Press; 2012.
- Ribeiro Neto ML, Jellis CL, Joyce E, Callahan TD, Hachamovitch R, Culver DA, Update in cardiac sarcoidosis. Annals ATS 16, 11, 2019, doi:10.1513/AnnalsATS.201902-119CME.
- Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. American Heart Journal. 2005;150: 459–463.
- Judson MA, Costabel U, Drent M, Wells A, Maier L, Koth L, et al. The WASOG sarcoidosis organ assessment instrument: un update of a previous clinical tool. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2014;31; 19–27.
- Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation. 2015;131: 624–632.
- Schulz-Menger J, Wassmuth R, Abdel-Aty H, Siegel I, Franke A, Dietz R, et al. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart. 2006;92: 399–400.
- Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. Journal of the American College of Cardiology. 2014;63: 329–336.
- Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, Vucinic-Mihailovic V, Artiko V, Saranovic D, et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. Journal of Nuclear Medicine. 2012;53: 1543–1549.
- Baughman RP, Judson MA, Wells A. The indication for the treatment of sarcoidosis: wells law. Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2017;34: 280–282. doi:10.36141/svdld.v34i4.6954.
- Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, Huong DL, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore). 2004;83: 315–334.
- Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Canadian Journal of Cardiology. 2013;29: 1034–1041.
- Nagai S, Yokomatsu T, Tanizawa K, Ikezoe K, Handa T, Ito Y, et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Internal Medicine. 2014;53: 427–433.
- Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythms. 2014;11: 1305–1323.
- Kiko T, Yoshihisa A, Kanno Y, Yokokawa T, Abe S, Miyata-Tatsumi M, et al. A multiple biomarker approach in patients with cardiac sarcoidosis. International Heart Journal. 2018;59: 996–1001.
- Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest. 2017;151: 139–148.